|
Pharmatech, Inc. Selects OmniComm Systems, Inc. As Its Preferred Electronic
Data Capture (EDC) Vendor And Enters Into A Strategic Partnership To Co-Develop
Next Generation Solutions For Improving Patient Accrual
CRO and EDC companies team up to co-develop a Patient Repository Solution for improving
patient accrual for their physicians conducting clinical trial research
FT. LAUDERDALE, FL - July 2, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin
Board: OMCM), one of the fastest growing companies in the EDC marketplace, today
announced that it will partner with Pharmatech, Inc., a Research Management Organization
(RMO), to build a patient registry database that will improve patient accrual in
clinical trials. The database will leverage the data mining functionality inherent
in OmniComm's First in Functionality™ TrialMasterTM EDC solution
to facilitate the screening and identification of patient candidates for cutting-edge
oncology research. OmniComm will be the exclusive choice for Pharmatech and their
network physicians who utilize EDC for clinical trials. Pharmatech will begin using
TrialMaster in a multi-center, Phase II clinical trial for advanced Non-Small Cell
Lung Cancer (NSCLC).
"OmniComm is pleased that Pharmatech chose our EDC solution, TrialMaster, for their
clients that want to benefit from the use of EDC. And more importantly, we share
a united vision with Pharmatech to bring new, integrated solutions for data mining
and patient accrual to the clinical development marketplace. This new Patient Repository
solution will create a pre-populated database of patient information that is linked
to our EDC solution and can be used by researchers to find patients quickly and
easily for their trials," commented Cornelis F. Wit, CEO of OmniComm Systems. Mr.
Wit added, "This will be the first of its kind solution between a CRO and an EDC
company that focuses on the problem of patient accrual. Pharmatech's unique status
as a CRO/SMO and tight affiliation with their network of physicians with access
to patient information, makes them the perfect partner to tackle this initiative."
Matthew Wiener, CEO of Pharmatech, states that, "The collaboration with OmniComm
allows Pharmatech to blend our expertise in the community-based oncology setting
with OmniComm's strength in the hospital and academic settings to provide real power
to oncology clinical trials. The OmniComm e-clinical trial platform will boost the
development of our progressive clinical trials business model by further building
upon our innovative patient enrollment and data management programs."
About Pharmatech
Pharmatech, Inc., (www.pharmatech.com) headquartered in Denver, Colorado, is a Research
Management Organization (RMO) dedicated to the highest quality of clinical research,
while protecting patient safety. Pharmatech provides services of a Site Management
Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology
clinical trials.
Pharmatech focuses on access to patients and clinical investigators through organized
research networks. The oncology network consists of over 1200 community-based cancer
researchers that provide innovative treatment options to cancer patients through
clinical trial opportunities. The Network model provides a foundation for the development
and utilization of therapeutic products among sponsors, investigators and patients.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions
to pharmaceutical, biotechnology, research and medical device organizations that
conduct life changing clinical trial research. OmniComm's growing base of satisfied
customers is a direct result of the company's commitment to deliver products and
services that ensure ease of use, faster study build, ease of integration and better
performance. OmniComm's client intuitive pricing model allows companies that range
from small to mid-size to large scale institutions to safely and efficiently capitalize
on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies
in North America during the last 5 years. In a market overview titled "The Promise
of Next-Gen eClinical Trial Software," by Forrester Research, OmniComm was given
the highest rating among its competitors for industry middleware. OmniComm Systems,
Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn,
Germany, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future
revenues and earnings, plans and objectives for the future operations, future agreements,
future economic performance, operations and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. OmniComm intends that such forward-looking statements be subject to
the Safe Harbors created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm's operations, markets and profitability,
actual results could differ materially and adversely from the expected results.
Back
|
